{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:43:22Z","timestamp":1773722602345,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00787-020-01589-2","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T19:02:30Z","timestamp":1593802950000},"page":"1047-1058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-134X","authenticated-orcid":false,"given":"Dominik","family":"St\u00e4mpfli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1087-7597","authenticated-orcid":false,"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea M","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"1589_CR1","unstructured":"World Health Organization (2018) International Classification of Diseases, 11th Revision (ICD-11)"},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1542\/peds.2011-2654","volume":"128","author":"American Academy of Pediatrics, Subcommittee on Attention-Deficit\/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management","year":"2011","unstructured":"American Academy of Pediatrics, Subcommittee on Attention-Deficit\/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics 128:1007\u20131022. https:\/\/doi.org\/10.1542\/peds.2011-2654","journal-title":"Pediatrics"},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/j.1475-6773.2012.01461.x","volume":"47","author":"M Matone","year":"2012","unstructured":"Matone M, Localio R, Huang Y-S, dosReis S, Feudtner C, Rubin D (2012) The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of US Medicaid-Enrolled Children. Health Serv Res 47:1836\u20131860. https:\/\/doi.org\/10.1111\/j.1475-6773.2012.01461.x","journal-title":"Health Serv Res"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0924-977X(03)00045-2","volume":"14","author":"S Kutcher","year":"2004","unstructured":"Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit\/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11\u201328. https:\/\/doi.org\/10.1016\/S0924-977X(03)00045-2","journal-title":"Eur Neuropsychopharmacol"},{"key":"1589_CR5","first-page":"18","volume":"7","author":"J Yanofski","year":"2010","unstructured":"Yanofski J (2010) The Dopamine Dilemma. Psychiatry Edgmont 7:18\u201323","journal-title":"Psychiatry Edgmont"},{"key":"1589_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40268-013-0034-4","volume":"13","author":"V Sikirica","year":"2013","unstructured":"Sikirica V, Fridman M, Bruno A, Hodgkins P, Erder MH (2013) Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit\/hyperactivity disorder. Drugs RD 13:271\u2013280. https:\/\/doi.org\/10.1007\/s40268-013-0034-4","journal-title":"Drugs RD"},{"key":"1589_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1089\/cap.2013.0107","volume":"24","author":"KA Betts","year":"2014","unstructured":"Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ (2014) Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit\/hyperactivity disorder during 2009. J Child Adolesc Psychopharmacol 24:260\u2013268. https:\/\/doi.org\/10.1089\/cap.2013.0107","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/cap.2018.0024","volume":"28","author":"O Scholle","year":"2018","unstructured":"Scholle O, Banaschewski T, Enders D, Garbe E, Riedel O (2018) Use and characteristics of antipsychotic\/methylphenidate combination therapy in children and adolescents with a diagnosis of attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol 28:415\u2013422. https:\/\/doi.org\/10.1089\/cap.2018.0024","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11920-013-0355-6","volume":"15","author":"D Linton","year":"2013","unstructured":"Linton D, Barr AM, Honer WG, Procyshyn RM (2013) Antipsychotic and psychostimulant drug combination therapy in attention deficit\/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability. Curr Psychiatry Rep 15:355. https:\/\/doi.org\/10.1007\/s11920-013-0355-6","journal-title":"Curr Psychiatry Rep"},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/1044546041649020","volume":"14","author":"MG Aman","year":"2004","unstructured":"Aman MG, Binder C, Turgay A (2004) Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243\u2013254. https:\/\/doi.org\/10.1089\/1044546041649020","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1589_CR11","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2019) MedDRA\u00ae: medical dictionary for regulatory activities terminology, 22nd edn. https:\/\/www.meddra.org\/"},{"key":"1589_CR12","unstructured":"Uppsala Monitoring Centre (2019) UMC | Know more about VigiBase. In: UMC Know More VigiBase. https:\/\/www.who-umc.org\/vigibase\/vigibase\/know-more-about-vigibase\/. Accessed 23 Apr 2019"},{"key":"1589_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1589_CR15","volume-title":"RStudio: integrated development for R","author":"RStudio Team","year":"2019","unstructured":"RStudio Team (2019) RStudio: integrated development for R. RStudio, Boston"},{"key":"1589_CR16","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"Core Team R (2019) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/chi.0b013e3180471b9d","volume":"46","author":"JB Levine","year":"2007","unstructured":"Levine JB, Deneys ML, Benjamin S (2007) Dystonia with combined antipsychotic and stimulant treatment. J Am Acad Child Adolesc Psychiatry 46:665\u2013666. https:\/\/doi.org\/10.1097\/chi.0b013e3180471b9d","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/01.chi.0000159166.96967.13","volume":"44","author":"E Benjamin","year":"2005","unstructured":"Benjamin E, Salek S (2005) Stimulant-atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry 44:510\u2013512. https:\/\/doi.org\/10.1097\/01.chi.0000159166.96967.13","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1089\/cap.2015.0225","volume":"26","author":"CA P\u00e9rez","year":"2016","unstructured":"P\u00e9rez CA, Garcia SS, Yu RD (2016) Extrapyramidal symptoms as a result of risperidone discontinuation during combination therapy with methylphenidate in a pediatric patient. J Child Adolesc Psychopharmacol 26:182\u2013182. https:\/\/doi.org\/10.1089\/cap.2015.0225","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1589_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.pediatrneurol.2007.05.017","volume":"37","author":"CP Hollis","year":"2007","unstructured":"Hollis CP, Thompson A (2007) Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Pediatr Neurol 37:287\u2013288. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2007.05.017","journal-title":"Pediatr Neurol"},{"key":"1589_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1089\/cap.2014.0148","volume":"25","author":"E Ince","year":"2015","unstructured":"Ince E, Algedik P, Demirdogen ES, Emul M, Demir T (2015) The relationship between acute dyskinesia with a single dose of methylphenidate and recent risperidone discontinuation in a child with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol 25:378\u2013379. https:\/\/doi.org\/10.1089\/cap.2014.0148","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/0269881107069466","volume":"21","author":"O Sabuncuoglu","year":"2007","unstructured":"Sabuncuoglu O (2007) Risperidone-to-methylphenidate switch reaction in children: three cases. J Psychopharmacol (Oxf) 21:216\u2013219. https:\/\/doi.org\/10.1177\/0269881107069466","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1589_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.9758\/cpn.2015.13.1.115","volume":"13","author":"G Guler","year":"2015","unstructured":"Guler G, Yildirim V, Kutuk MO, Toros F (2015) Dystonia in an adolescent on risperidone following the discontinuation of methylphenidate: a case report. Clin Psychopharmacol Neurosci 13:115\u2013117. https:\/\/doi.org\/10.9758\/cpn.2015.13.1.115","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1046\/j.1440-1754.2002.00719.x","volume":"38","author":"L Teoh","year":"2002","unstructured":"Teoh L, Allen H, Kowalenko N (2002) Drug-induced extrapyramidal reactions. J Paediatr Child Health 38:95\u201397. https:\/\/doi.org\/10.1046\/j.1440-1754.2002.00719.x","journal-title":"J Paediatr Child Health"},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/00004583-199611000-00006","volume":"35","author":"DJ Feeney","year":"1996","unstructured":"Feeney DJ, Klykylo W (1996) Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 35:1421\u20131422. https:\/\/doi.org\/10.1097\/00004583-199611000-00006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF02245439","volume":"114","author":"AAHP Megens","year":"1994","unstructured":"Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114:9\u201323. https:\/\/doi.org\/10.1007\/BF02245439","journal-title":"Psychopharmacology"},{"key":"1589_CR27","unstructured":"Jibson MD (2019) Second-generation antipsychotic medications: pharmacology, administration, and side effects. In: Marder S, Hermann R (eds) UpToDate. UpToDate, Waltham"},{"key":"1589_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/npp.2013.6","volume":"38","author":"BE Schmeichel","year":"2013","unstructured":"Schmeichel BE, Berridge CW (2013) Neurocircuitry underlying the preferential sensitivity of prefrontal catecholamines to low-dose psychostimulants. Neuropsychopharmacology 38:1078\u20131084. https:\/\/doi.org\/10.1038\/npp.2013.6","journal-title":"Neuropsychopharmacology"},{"key":"1589_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bmj.310.6979.575","volume":"310","author":"N Quinn","year":"1995","unstructured":"Quinn N (1995) Fortnightly review: drug treatment of Parkinson\u2019s disease. BMJ 310:575\u2013579. https:\/\/doi.org\/10.1136\/bmj.310.6979.575","journal-title":"BMJ"},{"key":"1589_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s002130000532","volume":"152","author":"S Silvestri","year":"2000","unstructured":"Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 152:174\u2013180","journal-title":"Psychopharmacology"},{"key":"1589_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40264-014-0204-5","volume":"37","author":"O Caster","year":"2014","unstructured":"Caster O, Juhlin K, Watson S, Nor\u00e9n GN (2014) Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf 37:617\u2013628. https:\/\/doi.org\/10.1007\/s40264-014-0204-5","journal-title":"Drug Saf"},{"key":"1589_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40290-019-00287-y","volume":"33","author":"R Beau-Lejdstrom","year":"2019","unstructured":"Beau-Lejdstrom R, Crook S, Spanu A, Yu T, Puhan MA (2019) Adverse drug reaction risk measures: a comparison of estimates from drug surveillance and randomised trials. Pharm Med 33:331\u2013339. https:\/\/doi.org\/10.1007\/s40290-019-00287-y","journal-title":"Pharm Med"},{"key":"1589_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archneurol.2011.117","volume":"68","author":"BJ Robottom","year":"2011","unstructured":"Robottom BJ, Factor SA, Weiner WJ (2011) Movement disorders emergencies part 2: hyperkinetic disorders. Arch Neurol 68:719\u2013724. https:\/\/doi.org\/10.1001\/archneurol.2011.117","journal-title":"Arch Neurol"},{"key":"1589_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1196\/annals.1444.005","volume":"1142","author":"DL Gilbert","year":"2008","unstructured":"Gilbert DL (2008) Drug-induced movement disorders in children. Ann N Y Acad Sci 1142:72\u201384. https:\/\/doi.org\/10.1196\/annals.1444.005","journal-title":"Ann N Y Acad Sci"},{"key":"1589_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Intern Med"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-020-01589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-020-01589-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-020-01589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T04:18:58Z","timestamp":1626841138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-020-01589-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1007\/s00787-020-01589-2","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest relevant to the content of this study. SW is a member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA). The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data used only contained anonymised and aggregated clinical information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}